A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated Influenza
Key facts
- Who runs it
- Boryung Biopharma Co., Ltd.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 348 people, planned
- Started
- Nov 2026
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BRC-201
- Placebo
- Record updated
- 17 November 2026
Who can take part
- Age
- 12 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Male or female participants aged 12 to less than 65 years who provide written informed consent or assent, as applicable
- Laboratory-confirmed influenza A and/or B infection by RIDT or PCR, with an axillary temperature ≥38.0°C and at least one systemic and one respiratory symptom of moderate or greater severity (score ≥2)
- Onset of influenza-related symptoms within 48 hours before randomization
- Willing and able to comply with the protocol-specified contraception requirements
- Able to comply with study procedures, scheduled visits, and symptom diary completion
Who cannot take part
- Suspected or confirmed lower respiratory tract disease on chest X-ray, recent acute respiratory infection, or concomitant infection requiring systemic antimicrobial treatment
- History of dysphagia, gastrointestinal conditions affecting drug absorption, or hypersensitivity to the investigational product, acetaminophen, or NSAIDs
- Use of anti-influenza medication within 7 days, or another investigational drug or device treatment within 30 days before randomization
- Severe or critical influenza infection requiring hospitalization or intensive care
- Significant uncontrolled underlying diseases or conditions associated with an increased risk of severe influenza, including immunodeficiency and clinically significant hepatic, renal, cardiovascular, or respiratory diseases
- BMI >30.0 kg/m², body weight <40.0 kg, or positive COVID-19 test at screening
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study
- Clinically significant infection-related findings, including leukocyte count >10.0 × 10⁹/L, purulent sputum, or purulent tonsillitis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 12 and 64 years old?
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Phase 3, multicenter, randomized, double-blind clinical study designed to evaluate the efficacy and safety of BRC-201 in adult and adolescent patients with acute uncomplicated influenza virus infection.
Read full original descriptionShow less
The study aims to assess the efficacy of BRC-201 in treating influenza symptoms and to evaluate its safety in patients with influenza.
The 2 groups in the trial
- BRC-201Treatment being tested
Participants will receive a single oral dose of BRC-201 (40 mg for participants weighing less than 80 kg or 80 mg for those weighing 80 kg or more).
- PlaceboPlacebo, for comparison
Participants will receive a single oral dose of placebo matching BRC-201 (2 capsules for participants weighing less than 80 kg or 4 capsules for those weighing 80 kg or more).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of BRC-201 in Adult and Adolescent Patients With Acute Uncomplicated Influenza Virus Infection
- Criteria questions
- Built from NCT07943390, who can take part
- Record updated
- 17 November 2026